Eytan Abraham

Dr. Eytan Abraham heads Lonza Personalized Medicine, which focuses on developing and bringing to market tools that enable research and development, scale out, and commercialization of patient scale cell therapies, with an emphasis on decentralized and point of care manufacturing. Prior to this Eytan led Lonza’s Cell and Viral Therapy R&D for five years, focusing on developing manufacturing solutions for the Cell and Gene therapy continuum. Prior to Lonza, Dr. Abraham was head of therapeutic pipeline development at Pluristem Therapeutics, developing stem cell therapies for cardiovascular indications. Dr. Abraham holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School.